Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 14/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 11/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 11/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 11/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 9/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10201115 | 0.81 | MAPK1 (0.55) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL10201100 | 0.76 | HCAR3 (0.39) | — | |
| SCHEMBL1552411 | 0.76 | CHRNB2 (0.51) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL9033586 | 0.75 | PEPD (0.38) | MAPK1 | |
| SCHEMBL27897933 | 0.73 | RAB9A (0.74) | — | |
| SCHEMBL1933915 | 0.72 | MAPK1 (0.63) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL29351108 | 0.71 | RAB9A (0.74) | — | |
| SCHEMBL5449305 | 0.70 | PIK3CA (0.70) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL5454854 | 0.70 | PIK3CA (0.66) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL4675273 | 0.70 | PIK3CA (0.60) | PIK3CAMAPK8MAPK9MAPK10MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569336-B2 | Compounds for the treatment of inflammatory disorders | TONG LING (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569336-B2 | Compounds for the treatment of inflammatory disorders | TONG LING (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TONG LING (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TONG LING (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, ADAMTS1, ADAMTS7 | PIK3CA 3211/4885MAPK8 1346/4885MAPK9 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.